INDSWFTLTD Stock View

Ind Swift Ltd
stock-view-header

₹ 20.7

icon -0.41 | -1.97
Market Cap ₹( Cr.)
1,164.54
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
24-Sep-2023
 

The average score for Ind Swift Ltd stands at 10 against 8, three months back.

Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company. The Company operates in both domestic and export markets. It is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The Company is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. It operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The Company also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. It has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The Company also has five plants in India.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
17.06
100 DMA(₹)
13.15
200 DMA(₹)
11.30
52 Weeks Range
6.50     24.29

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required